ABSTRACT
There has been significant research and therapeutic activity within the healthcare sector in response to the coronavirus disease 2019 (COVID-19). In the United States, a complementary and alternative medicine (CAM) treatment regimen for improving patients' immune systems against COVID-19 prophylaxis includes excess zinc, vitamin C, and vitamin D supplementation administered over a seven-day period. Despite the fact that zinc and other mineral supplements are becoming increasingly popular in Western culture, clinical research on CAM remains limited. This case series examines three patients treated with a surplus of zinc tablets for COVID-19 prophylaxis who presented with moderate-to-severe hypoglycemia. Varying amounts of glucose were administered to these patients to offset their low blood sugar levels. Medical staff noted a positive Whipple's triad in two of the patients but observed no other abnormalities in the laboratory values. All three patients were instructed to cease zinc tablet intake upon discharge. Our findings raise awareness of the potential dangers associated with mineral supplements and serve as a warning for those seeking CAM treatment options.
ABSTRACT
We conducted a seroprevalence survey to estimate the true number of infections with SARS-CoV-2, the virus that causes COVID-19, in King County as of August 2020 by measuring the proportion of residents from who had antibodies against the virus. Participants from 727 households took part in a cross-sectional address-based household survey with random and non-random samples and provided dried blood spots that were tested for total antibody against the viral nucleocapsid protein, with confirmatory testing for immunoglobulin G against the spike protein. The data were weighted to match King County's population based on sex, age group, income, race, and Hispanic status. After weighting and accounting for the accuracy of the tests, our best overall estimate of anti-SARS-CoV-2 seroprevalence in King County as of August 2020 is 3.9% (95% confidence interval (CI) 2.4%-6.0%) with an effective sample size of 589. Comparing seroprevalence with positive test reports, our survey suggests that viral testing underestimated incidence by a factor of about five and suggests that the proportion of cases that were serious (based on hospitalization) or fatal was 2.4% and 0.8%, respectively. Prevalence varied by subgroup; households reporting incomes at or below $100,000 in 2019 had nearly five times higher estimated antibody prevalence than those with incomes above $100,000. Those reporting non-White/non-Asian race had roughly seven times higher estimated antibody prevalence than those reporting White race. This survey was noteworthy for including people of all ages; among all age groups, the weighted estimate of prevalence was highest in older teens and young adults and lowest in young children, although these differences were not statistically significant.